Literature DB >> 21080395

Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance.

Sabine Klüter1, Jeffrey R Simard, Haridas B Rode, Christian Grütter, Vijaykumar Pawar, Hans C A Raaijmakers, Tjeerd A Barf, Matthias Rabiller, Willem A L van Otterlo, Daniel Rauh.   

Abstract

Targeting protein kinases in cancer therapy with irreversible small-molecule inhibitors is moving to the forefront of kinase-inhibitor research and is thought to be an effective means of overcoming mutation-associated drug resistance in epidermal growth factor receptor kinase (EGFR). We generated a detection technique that allows direct measurements of covalent bond formation without relying on kinase activity, thereby allowing the straightforward investigation of the influence of steric clashes on covalent inhibitors in different resistant kinase mutants. The obtained results are discussed together with structural biology and biochemical studies of catalytic activity in both wild-type and gatekeeper mutated kinase variants to draw conclusions about the impact of steric hindrance and increased catalytic activity in drug-resistant kinase variants.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21080395     DOI: 10.1002/cbic.201000352

Source DB:  PubMed          Journal:  Chembiochem        ISSN: 1439-4227            Impact factor:   3.164


  5 in total

1.  Covalent docking using autodock: Two-point attractor and flexible side chain methods.

Authors:  Giulia Bianco; Stefano Forli; David S Goodsell; Arthur J Olson
Journal:  Protein Sci       Date:  2015-07-07       Impact factor: 6.725

2.  Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib.

Authors:  Juan Manuel Domínguez; Ana Fuertes; Leyre Orozco; María del Monte-Millán; Elena Delgado; Miguel Medina
Journal:  J Biol Chem       Date:  2011-11-18       Impact factor: 5.157

3.  Covalent Modifiers: A Chemical Perspective on the Reactivity of α,β-Unsaturated Carbonyls with Thiols via Hetero-Michael Addition Reactions.

Authors:  Paul A Jackson; John C Widen; Daniel A Harki; Kay M Brummond
Journal:  J Med Chem       Date:  2016-12-20       Impact factor: 7.446

4.  Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Authors:  Suresh S Ramalingam; Fiona Blackhall; Maciej Krzakowski; Carlos H Barrios; Keunchil Park; Isabel Bover; Dae Seog Heo; Rafael Rosell; Denis C Talbot; Richard Frank; Stephen P Letrent; Ana Ruiz-Garcia; Ian Taylor; Jane Q Liang; Alicyn K Campbell; Joseph O'Connell; Michael Boyer
Journal:  J Clin Oncol       Date:  2012-07-02       Impact factor: 44.544

5.  Irreversible inhibitors of c-Src kinase that target a nonconserved cysteine.

Authors:  Frank E Kwarcinski; Christel C Fox; Michael E Steffey; Matthew B Soellner
Journal:  ACS Chem Biol       Date:  2012-09-05       Impact factor: 5.100

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.